Cytek Biosciences vs 10x Genomics
10x Genomics reported revenue of $643 million in fiscal 2025, 3.2 times Cytek Biosciences' $202 million in fiscal 2025. Cytek Biosciences' revenue grew 0.5% in its latest year, and 10x Genomics' grew 5.2%. Cytek Biosciences had an operating margin of -20.0%, against -9.5% at 10x Genomics. Free cash flow was −$9 million at Cytek Biosciences and $130 million at 10x Genomics.
Side by side
| Cytek Biosciences | 10x Genomics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $202M | $643M |
| Revenue growth | 0.5% | 5.2% |
| Revenue growth a year, last 5 years | 210.3% | 16.6% |
| Gross margin | 51.8% | 69.0% |
| Operating margin | −20.0% | −9.5% |
| Net margin | −33.0% | −6.8% |
| Free cash flow | −$9M | $130M |
| Free cash flow margin | −4.3% | 20.2% |
| Return on capital | — | −16.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $15M | $0M |
| Change in diluted share count | −2.2% | 3.6% |
| Last close | $5.84 | $58.19 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $18.8 million |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cytek Biosciences10x Genomics
Operating margin
Percent of revenue
Cytek Biosciences10x Genomics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cytek Biosciences10x Genomics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytek Biosciences and 10x Genomics pages.